ISOFOL

Isofol Medical

Market Cap 916.5M

Isofol Medical is a Swedish biotech company developing Modufolin, a new folate-based therapy used in the treatment of colorectal cancer and as a rescue therapy after high-dose chemotherapy treatment. The company was founded in 2008 through a collaboration between Professor Bengt Gustavsson and Merck & Cie. Isofol Medical is based in Gothenburg and is listed at First North Premier since April 2017.

+ more
0.00
Today
Day High
29.00
29
Day Low
28.30
Day Open
28.80
Prev Close
29.00
VWAP
28.9
Volume
25K
Turnover
0.722M
Top Broker
VWAP
27.1
Avg Volume
130K
Avg Turnover
3.530M
Top Brokers
CAR/ENS
VWAP
26.4
Avg Volume
99K
Avg Turnover
2.608M
Top Brokers
CAR/ENS
VWAP
26.1
Avg Volume
56K
Avg Turnover
1.470M
Top Brokers
CAR/ENS
52 week summary
Price Range
20.0
Last
29.3
Beta
N/A
Market Cap
916.5M
Total Return
7.4%
Trailing P/E
-14.7
Div Yield
0.0%
Shares Outstanding
31.6M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 35.1%
Change 12 Months -1.7%
Volume Trend
Average Volume 10 vs 60 Days 148.7%
Price VS
52 Week High -1.0%
50 Day Moving Average 23.1%
200 Day moving Average 28.5%

Add article markers

Compare Isofol Medical to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Anders Rabbe, CEO
  • Sven Erickson, CFO
  • Executive board
  • Jan-Eric Österlund, Chairman of the board
Last updated: 2017-10-21 Source: Redeye
Major Owners Equity Votes
Biofol AB 10.8%
10.8%
Handelsbanken Fonder 8.2%
8.2%
Peak Partners 5.8%
5.8%
Danica Pension 3.5%
3.5%
Swedbank Robur Fonder 3.3%
3.3%
Yield Life Science AB (Publ) 3.1%
3.1%
Rhenman Healthcare Equity L/S 2.5%
2.5%
Svenska Handelsbanken AB for PB 2.5%
2.5%
Urus AB 2.4%
2.4%
AFA Försäkring 2.2%
2.2%
Last updated: 2017-10-21 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
162
0 Sales
0
Last 24 weeks
1 Purchases
162
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 32.5
  •  
  • -6.3
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  •  
  • 52.9%
  • 0.0%
  • -6
  • -2
  • 0.0
  • 2014
  •  
  •  
  • 6
  • 2
  • 0
  • 0
  • 8
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 1
  • 0
  • 9
  •  
  •  
  • 0
  • 4
  • 0
  • 4
  • 0
  • 0
  • 0
  • 4
  • 0
  • 0
  • 5
  • 0
  • 5
  • 9
  • 2014
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • -1
  • 2
  • 2014 Q4
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 32.5
  •  
  • -7.2
  • 0.0
  • 0.0
  • 0.0
  • -0.9
  • 0.0
  • 0.0
  • 0.0
  •  
  • 16.8%
  • 0.0%
  • -7
  • -6
  • 0.8
  • 2015
  •  
  •  
  • 7
  • 2
  • 0
  • 0
  • 9
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 10
  •  
  •  
  • 0
  • 8
  • 0
  • 8
  • 0
  • 0
  • 0
  • 8
  • 0
  • 0
  • 2
  • 0
  • 2
  • 10
  • 2015
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 4
  • 0
  • 4
  • 2015 Q1
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016
  •  
  • -1,562.5%
  • -1,562.4%
  • 1,157.2%
  • -1,599,375.0%
  • -1,602,675.0%
  • -1,602,725.0%
  •  
  • -1.97
  • -1.97
  • 0.00
  •  
  • 32.5
  •  
  • -392.2
  • 0.0
  • 0.0
  • 0.0
  • -98,059.0
  • 6.1
  • 6.1
  • 0.0
  •  
  • 27.9%
  • 0.0%
  • -392
  • -386
  • 0.0
  • 2016
  •  
  •  
  • 392
  • 4
  • 0
  • 0
  • 396
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 396
  •  
  •  
  • 0
  • 17
  • 0
  • 17
  • 0
  • 0
  • 0
  • 17
  • 0
  • 0
  • 7
  • 0
  • 7
  • 23
  • 2016
  • 0
  • -64
  • 0
  • -64
  • 0
  • -64
  • 0
  • -64
  • 7
  • 0
  • -57
  • 2016 Q1
  • 0
  • -15
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • -15
  • 2016 Q2
  • 0
  • -11
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • -11
  • 2016 Q3
  • 0
  • -8
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • -8
  • 2016 Q4
  • 0
  • -31
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • -31
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-10-25 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.

Community Posts

Be the first to write something about this company in the community.

Create new post